Atezolizumab-obinutuzumab-venetoclax in follicular lymphoma and MZL
Charles Herbaux, MD, MSc, University Hospital of Lille, Lille, France, gives an overview of the findings of the primary analysis of a Phase II trial of atezolizumab plus venetoclax and obinutuzumab for the treatment of patients with relapsed/refractory follicular lymphoma and marginal zone lymphoma (MZL). 58 patients with follicular lymphoma were enrolled in the trial with a median follow-up of 14.5 months, and 20 patients with MZL were enrolled in the trial with a median follow-up of 11.9 months. The follicular lymphoma cohort reported an overall response rate (ORR) of 53.6% and the MZL cohort reported an ORR of 66.76%. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Watch video Atezolizumab-obinutuzumab-venetoclax in follicular lymphoma and MZL online without registration, duration hours minute second in high quality. This video was added by user VJHemOnc – Video Journal of Hematology & HemOnc 11 June 2021, don't forget to share it with your friends and acquaintances, it has been viewed on our site 159 once and liked it 0 people.